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A B S T R A C T
Objectives: We compared a 3rd generation (gen) and two 4th gen HIV enzyme immunoassays (EIA) to
pooled nucleic acid testing (PNAT) for the identiﬁcation of pre- and early seroconversion acute HIV
infection (AHI).
Study Design: 9550 specimens from males >18 year from clinics attended by men who have sex with men
were tested by Siemens ADVIA Centaur1 HIV 1/O/2 (3rd gen) and HIV Combo (4th gen), as well as by
Abbott ARCHITECT1 HIV Ag/Ab Combo (4th gen). Third gen non-reactive specimens were also tested by
Roche COBAS1 Ampliprep/COBAS1 TaqMan HIV-1 Test v.2 in pools of 24 samples. Sensitivity and
speciﬁcity of the three EIAs for AHI detection were compared.
Results: 7348 persons contributed 9435 specimens and had no evidence of HIV infection, 79 (94
specimens) had established HIV infection, 6 (9 specimens) had pre-seroconversion AHI and 9 (12
specimens) had early seroconversion AHI. Pre-seroconversion AHI cases were not detected by 3rd gen
EIA, whereas 2/6 (33.3%) were detected by Siemens 4th gen, 4/6 (66.7%) by Abbott 4th gen and 6/6 (100%)
by PNAT. All three EIAs and PNAT detected all individuals with early seroconversion AHI. Overall
sensitivity/speciﬁcity for the EIAs relative to WB or NAT resolved infection status was 93.6%/99.9% for
Siemens 3rd gen, 95.7%/99.7% for Siemens 4th gen and 97.9%/99.2% for Abbott 4th gen.
Conclusions: While both 4th gen EIAs demonstrated improved sensitivity for AHI compared to 3rd gen
EIA, PNAT identiﬁed more AHI cases than either 4th gen assay. PNAT is likely to remain a useful strategy to
identify AHI in high-risk populations.
ã 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Individuals with acute HIV infection (AHI) have high viral loads
and have been reported to account for up to 50% of forward HIV
transmissions [1–3], making early diagnosis a public health
priority to reduce HIV transmission and to facilitate early
engagement of individuals into care. Currently available 3rd
generation (gen) HIV enzyme immunoassays (EIA) can detect
HIV infection in those with early stage HIV seroconversion [4], butAbbreviations: EIA, enzyme immunoassay; NAT, nucleic acid test; PNAT, pooled
nucleic acid test; gen, generation; AHI, acute HIV infection; WB, western blot.
* Corresponding author at: Clinical Prevention Services, BC Centre for Disease
Control, Vancouver, BC V5Z 4R4, Canada. Tel.: +1 604 707 2421; fax: +1604 707 2420.
E-mail address: mel.krajden@bccdc.ca (M. Krajden).
http://dx.doi.org/10.1016/j.jcv.2014.06.024
1386-6532/ã 2014 The Authors. Published by Elsevier B.V. This is an open access article unthese assays fail to identify AHI when viral loads are typically very
high and antibodies have not reached sufﬁcient levels to be
detectable [5,6]. HIV nucleic acid tests (NAT), or p24 antigen assays
(either stand-alone assays or when incorporated into 4th gen EIAs),
can assist with detection of pre-seroconversion HIV infections,
with the former exhibiting greater sensitivity and a shorter
window period between infection and detection of HIV antibodies
[7].
HIV conﬁrmatory algorithms have changed very little since
their introduction in the 1980s. While HIV screening EIAs have
become more sensitive over time and display shorter window
periods, the HIV western blot (WB) has not evolved in tandem with
the WB assay having a longer window period than current 3rd and
4th gen EIAs [7]. Consequently, algorithms using WB usually
cannot conﬁrm HIV infection during the acute phase [8]. In 2010,der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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a new HIV testing algorithm, both to improve identiﬁcation of AHI
and to discriminate HIV-1 from HIV-2 infections. The proposed
algorithm recommends screening with a sensitive 4th gen EIA and
replaces the WB with a supplemental HIV-1/HIV-2 differential
antibody assay to conﬁrm the presence of HIV-1 and/or HIV-2
antibodies [9]. Specimens with a reactive primary EIA and a non-
reactive or indeterminate differential assay are then tested for HIV
nucleic acid to identify AHI prior to detection of HIV antibodies. A
number of recent studies have demonstrated the utility of the
proposed algorithm for conﬁrming HIV infection and improving
the detection of AHI [10–12].
Studies have shown that the use of pooled NAT (PNAT) for
specimens with a non-reactive antibody screen test increases the
diagnostic yield of AHI [5], especially in high-risk populations [13–
16]. We previously showed that the use of PNAT among males at
high risk of HIV infection with a non-reactive 3rd gen EIA led to
increased detection of AHI [6]. However, HIV screening algorithms
are now switching to preferential use of 4th gen EIAs, and the
relative contribution of PNAT with respect to 4th gen EIAs is lessFig. 1. HIV testing algorithm.
Abbreviations: gen: generation; EIA: enzyme immunoassay; NAT: nucleic acid test; newell understood. In this study, we compare the performance of




Six clinics in Vancouver, British Columbia with historically high
HIV detection rates among men who have sex with men were
included in the study [6]. All HIV test requests received from these
clinics between September 2012 and September 2013 for male,
transgendered and sex unspeciﬁed individuals >18 year were
included. Specimens were excluded from analysis if there was
insufﬁcient volume of serum for all tests.
2.2. Laboratory methods
All serum specimens were screened by a 3rd gen (Siemens
ADVIA Centaur1 HIV-1/O/2; Siemens, Mississauga, Ontario,g: negative; indet: indeterminate; pos: positive.
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Combo and Abbott ARCHITECT1 HIV Ag/Ab Combo; Abbott
Diagnostics, Mississuaga, Ontario, Canada) (Fig. 1). The Centaur1
instrument uses a single disposable pipette tip for each sample
tested, whereas the ARCHITECT1 uses a single probe with washing
between specimens. To reduce the possibility of RNA cross-
contamination following serological screening of samples on the
Centaur1, aliquots were removed for subsequent testing by
ARCHITECT1, PNAT and individual NAT. EIA results were classiﬁed
as reactive if the signal/cutoff (s/c) ratio was 1.00 and non-
reactive if the s/c was <1.00. Third gen EIA reactive specimens were
tested by HIV WB (Bio-Rad Genetic Systems HIV-1 Western Blot;
BioRad Montreal, Quebec, Canada) and/or HIV NAT (Roche COBAS1
AmpliPrep/COBAS1 TaqMan HIV-1 Test, v.2; Roche Diagnostics,
Laval, Quebec, Canada) to conﬁrm HIV infection. Specimens non-
reactive by 3rd gen, but reactive by 4th gen EIA or positive by PNAT
are not routinely tested by WB. WB is not useful for HIV
conﬁrmation in these cases due to the longer window period of
WB compared to current 3rd and 4th gen EIAs [7,9]. All EIAs and
PNAT was conducted on fresh specimens which had not been
frozen.
Specimens with a non-reactive 3rd gen EIA were combined into
pools of 24 for PNAT and the pools tested by COBAS1 TaqMan HIV-
1 test as previously described [6]. While the licensed use of this
NAT is for viral load monitoring, we performed in-house validation
and veriﬁcation of the assay for use as a supplementary HIV
diagnostic test and for PNAT (data not shown). A pool size of 24
specimens was chosen to minimize screening costs while
maintaining a reasonable HIV RNA detection sensitivity (i.e., about
500 copies/mL) [17] and turnaround time for results. PNAT positive
pools were deconstructed to identify the HIV-1 RNA positive
specimen(s) [18]. Occasionally, insufﬁcient volume of sample was
available for re-testing a RNA positive pooled sample by individual
NAT; in these cases, the sample was diluted with HIV RNA negative
serum matrix (Acrometrix1 Ultra Serum Dilution Matrix; Applied
Biosystems/Life Technologies, Burlington, Ontario, Canada) before
testing and the RNA copy number was adjusted for the dilution
factor. For PNAT negative pools, all specimens in the pool were
reported as HIV-1 NAT negative and HIV antibody non-reactive.
Third and/or 4th gen EIA non-reactive, NAT positive specimens
were reported presumptively as consistent with AHI, and HIV
infection was conﬁrmed by follow-up serologic and/or viral load
testing.Table 1
HIV 3rd and 4th generation EIA and pooled NAT results by HIV infection category.
Siemens 3rd gen
No evidence of HIV infection Reactive 13 
Non-reactive 9422 
Not tested 0 
Established HIV infectiona Reactive 79 
Non-reactive 0 
Not tested 0 
Pre-seroconversion HIV infectiona Reactive 0 
Non-reactive 6 
Indeterminate 0 
Not tested 0 
Early seroconversion HIV infectiona Reactive 9 
Non-reactive 0 
Indeterminate 0 
Not tested 0 
gen: generation; NAT: HIV-1 nucleic acid test; WB: HIV-1 western blot.
a In cases where more than one sequential specimen was received per individual, re2.3. Case deﬁnitions
HIV positive case deﬁnitions were based on the ﬁrst HIV
positive specimen for an individual. Established HIV infection was
deﬁned as a reactive 3rd and 4th gen EIA followed by a positive WB.
Earlyseroconversion AHI cases were those individuals with
reactive 3rd and 4th gen EIAs and an indeterminate or negative
WB, together with a positive HIV-1 NAT. Pre-seroconversion AHI
cases were those individuals with a non-reactive 3rd gen EIA,
reactive or non-reactive 4th gen EIA, and a positive HIV-1 NAT.
Individuals with non-reactive 3rd and 4th gen EIAs and a negative
PNAT, as well as individuals with one or more reactive EIAs
(presumptive false reactives) together with a negative individual
NAT, were deﬁned as having no evidence of HIV infection.
2.4. Statistical analysis
Sensitivities for established, pre-seroconversion and early
seroconversion HIV infection, and speciﬁcities were calculated
for each assay. For HIV uninfected subjects, each HIV negative
specimen was included in the analysis (i.e., individuals contribut-
ing more than one negative sequential specimen were included
multiple times). For HIV-infected subjects with more than one
sequential specimen received after the initial diagnosis, only the
results of the ﬁrst specimen were used for rate and sensitivity
calculations. The rates of overall HIV detection for each of the EIAs
and PNAT were calculated, together with the percent incremental
AHI yield for both 4th gen EIAs and PNAT.
3. Results
Of 9597 specimens received between September 2012 and
September 2013, 47 were excluded from analysis due to insufﬁ-
cient serum volume. The ﬁnal dataset consisted of 9550 specimens
from 7442 unique individuals. The overall conﬁrmed HIV infection
rate for this tested population was 1.3% (94/7,442). Of these, 7348
(98.7%) individuals (9435 specimens) had no evidence of HIV
infection, established HIV infection was identiﬁed in 79 individuals
(94 specimens), early seroconversion AHI in 9 individuals (12
specimens), and pre-seroconversion AHI in 6 individuals (9
specimens) (Table 1). All three EIAs were reactive for individuals
with established HIV infection and early seroconversion AHI. For
those with pre-seroconversion AHI, 0/6 (0.0%), 2/6 (33.3%), 4/6 Siemens 4th gen Abbott 4th gen NAT WB
33 74 0 0
9402 9361 9435 0
0 0 0 9435
79 79 4 79
0 0 0 0
0 0 75 0
2 4 6 0
4 2 0 1
0 0 0 1
0 0 0 4
9 9 9 0
0 0 0 1
0 0 0 8
0 0 0 0
sults for only the ﬁrst specimen are shown in the table.
Table 2
Detailed results for specimens from pre- and early seroconversion HIV infection.
Category Subject Collect date Siemens 3rd gen s/c Siemens 4th gen s/c Abbott 4th gen s/c NAT HIV RNA copies/mL WB
Pre-seroconversion 1 29/10/2012 NR <0.05 NR 0.658 NR 0.30 POS 80,472 NT
05/11/2012 NR <0.05 R 7.319 R 8.90 POS 2,142,512 NT
2 08/08/2013 NR <0.05 NR 0.180 NR 0.28 POS 5,802 NT
15/08/2013 NR 0.08 R >12.00 R 23.20 POS NQ INDET
3 09/08/2013 NR <0.05 NR 0.716 R 1.14 POS 169,626 NT
18/08/2013 R 4.35 R >12.00 R 472.88 POS >10,000,000 NEG
4 09/08/2013 NR 0.20 R >12.00 R 116.00 POS NQ INDET
5 31/08/2013 NR <0.05 NR 0.927 R 2.10 POS 223,036 NT
06/09/2013 NR 0.44 R 9.139 R 26.39 NT – INDET
6 02/10/2012 EQ 0.86 R 2.929 R 5.36 POS 750,650 NEG
10/10/2012 R >50.00 R >12.00 R 21.49 POS NQ INDET
Early seroconversion 1 12/09/2012 R 6.39 R >12.00 R 104.14 POS >10,000,000 INDET
2 04/12/2012 R >50.00 R >12.00 R 14.57 POS 13,265 INDET
3 13/03/2013 R 13.45 R 8.45 R 3.13 POS 112,019 INDET
4 17/05/2013 R 18.17 R >12.00 R 70.93 POS NQ INDET
5 31/05/2013 R 19.57 R 11.40 R 26.55 POS 1,231,879 INDET
6 13/06/2013 R 6.82 R 4.09 R 11.84 POS 556,587 INDET
7 17/06/2013 R 5.34 R >12.00 R 110.26 POS NQ INDET
21/06/2013 R 31.58 R >12.00 R 61.15 POS NQ INDET
8 02/07/2013 R 5.26 R >12.00 R 246.18 POS >10,000,000 INDET
9 12/08/2013 R 15.94 R >12.00 R 32.79 POS >10,000,000 NEG
gen: generation; s/c: signal/cutoff ratio; gen: generation; NAT: HIV-1 nucleic acid test; WB: HIV-1 western blot; NR: non-reactive; R: reactive; EQ: equivocal; NQ: not
quantiﬁed (specimens not quantiﬁed had low HIV target cycle threshold values signifying a positive result; however, an invalid result was returned as a result of saturation by
very high HIV RNA copy numbers); NT: not tested; POS: positive; NEG: negative; INDET: indeterminate.
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4th gen, Abbott 4th gen and PNAT respectively. Detailed EIA, NAT
and WB results for the early and pre-seroconversion subjects are
shown in Table 2. These data illustrate the very high HIV RNA copy
numbers often observed during pre-seroconversion and early
seroconversion AHI, even when testing serum, which is sub-
optimal for measuring HIV RNA by NAT.
Sensitivity and speciﬁcity calculations are shown in Table 3,
together with 95% conﬁdence intervals, for the EIAs and PNAT.
More pre-seroconversion AHI were detected by PNAT than by
either the Abbott 4th gen or Siemens 4th gen, and both 4th gen
EIAs detected more pre-seroconversion AHI than the 3rd gen EIA.
For this high-risk population, the incremental AHI yield compared
to 3rd gen screening for Siemens 4th gen, Abbott 4th gen and PNAT
was 2.1%, 4.3% and 6.4% respectively.
Of the four pre-seroconversion AHI cases not detected by
Siemens 4th gen, one had a high non-reactive s/c value (0.927)
which would have resulted in a conﬁrmatory NAT if an equivocal
range (e.g., s/c 0.80–0.99) was used to trigger additional testing for
AHI. However, among the NAT negative, HIV EIA non-reactive
subjects, 457 specimens had Siemens 4th gen s/c values in the
equivocal range (Supplementary Fig. S1). Thus, a considerable
number of individual NATs would need to be performed for
equivocal EIA results for this assay to provide one additional AHI
diagnosis. PNAT for specimens with equivocal EIA results would
reduce the number of NATs required and may identify additionalTable 3
Sensitivity and speciﬁcity of 3rd and 4th generation EIAs and pooled NAT by HIV infec
N Siemens 3rd gen (95% CI) Si
Sensitivitya(established HIV) 79 100.00% (94.2–100.0%) 10
Sensitivitya(pre-seroconversion HIV) 6 0.00% (0.0–48.3%) 33
Sensitivitya(early seroconversion HIV) 9 100.00% (62.9–100.0%) 10
Sensitivitya(overall) 94 93.60% (86.1–97.4%) 95
Speciﬁcity 9,435 99.90% (99.8–99.9%) 99
gen: generation; 95% CI: 95% conﬁdence interval; NAT: HIV-1 nucleic acid test; NC: not 
a In cases where more than one specimen was received over time per individual, resAHI cases that would be missed without the use of an equivocal
range. In contrast, the Abbott 4th gen assay had 20 equivocal
results, none of which were positive by NAT.
Supplementry material related to this article found, in the
online version, at http://dx.doi.org/10.1016/j.jcv.2014.06.024.
The distribution of the s/c ratios for the three EIAs is shown in
Supplementary Fig. 1. The Siemens 3rd gen EIA had fewer non-
reactive s/c values near the cutoff than either 4th gen assay. Of the
33 falsely reactive Siemens 4th gen results in the HIV uninfected
group, none were reactive by Abbott 4th gen. Similarly, none of the
74 falsely reactive Abbott 4th gen results were reactive by Siemens
4th gen. False reactive EIA results generally had s/c values much
closer to the cutoff than those for conﬁrmed HIV infections
(Table 4).
4. Discussion
We demonstrated that the use of 4th gen HIV EIA screening and
PNAT enhance AHI detection compared to a 3rd gen EIA, although
neither 4th gen assay compared in this study was reactive for all
PNAT-detected AHI cases. The number of pre-seroconversion AHI
cases in our study was small and therefore the data are not
sufﬁciently robust to demonstrate a statistically signiﬁcantly
higher rate of AHI detection by 4th gen vs. 3rd gen assays.
However, we believe our data do support the use of 4th gen assays
for HIV screening to identify AHI cases that would otherwise betion category.
emens 4th gen (95% CI) Abbott 4th gen (95% CI) NAT (95% CI)
0.00% (94.2–100.0%) 100.00% (94.2–100.0%) NC
.30% (6.0–75.9%) 66.70% (24.1–94.0%) 100.00% (51.7–100.0%)
0.00% (62.9–100.0%) 100.00% (62.9–100.0%) 100.00% (62.9–100.0%)
.70% (88.8–98.6%) 97.90% (91.8–99.6%) NC
.70% (99.5–99.8%) 99.20% (99.0–99.4%) 100.00% (99.9–100.0%)
calculated (only a small portion of established HIV specimens were tested by NAT).
ults for only the ﬁrst specimen were used for sensitivity calculations.
Table 4
Median signal/cutoff values for false reactive EIA vs. conﬁrmed reactive EIA.
Median false reactive s/c (range) Median conﬁrmed reactive s/c (range)
Siemens 3rd gena
1.50 (1.08–2.93) 50.00 (<0.05–>50.00)
Siemens 4th genb 1.23 (1.02–4.03) 12.00 (0.18–>12.00)
Abbott 4th gen 2.32 (1.01–23.83) 365.17 (0.28–1045.46)
gen: generation; s/c: signal/cutoff.
a For s/c values <0.05 and >50.00, the median was determined by substituting the values 0.05 and 50.00 respectively.
b For s/c values >12.00, the median was determined by substituting a value of 12.00.
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incremental AHI yield of PNAT compared to 4th gen screening
[11,19–21], and our data add to the limited literature.
The 6.4% incremental AHI yield for PNAT in this analysis is lower
than the 11.5% we previously reported for the same clinic
population. The earlier study used social marketing campaigns
to promote AHI awareness as well as early and more frequent
testing among men who have sex with men [6]. The lower AHI
yield might reﬂect the lack of social marketing during the present
study period, lower incidence rates within the population testing
at these clinics, or the effects of a provincial HIV treatment as
prevention initiative [22].
The algorithm used for AHI conﬁrmation differs slightly from
that proposed by the CDC [8], i.e., a WB was used for HIV
antibody conﬁrmation rather than a HIV-1/HIV-2 discriminatory
assay. However, our results conﬁrm the value of incorporating
NAT into HIV testing algorithms. We demonstrated that WB for
conﬁrmation of HIV infection during the pre- and early
seroconversion phases of AHI adds little or no value, as the
WB was negative or indeterminate for the cases tested. The
addition of HIV NAT to the algorithm provides presumptive and
timely conﬁrmation of AHI without the delay associated with
serologic follow-up. However, our standard protocol is to obtain
follow up HIV serology to conﬁrm seroconversion in AHI cases.
Our data also demonstrate the value of supplementary EIA
testing to help identify false reactivity of HIV screen tests. Of
the falsely reactive 4th gen tests among HIV-uninfected
individuals in the study population, none was reactive with
the other 4th gen assay.
A potential concern with regard to PNAT of specimens that have
been pre-screened on automated serology analyzers is carryover of
HIV RNA between specimens. The Siemens ADVIA Centaur1
instrument uses a separate pipette tip for each specimen, whereas
the Abbott ARCHITECT1 uses a common probe which is washed
between specimens. Since we removed aliquots of serum for PNAT/
individual NAT prior to testing samples on the ARCHITECT1
instrument, we believe the risk of HIV RNA cross-contamination in
this study is very low. However, if specimens are ﬁrst screened
with e.g., the Abbott ARCHITECT1 instrument, the potential for
RNA carryover needs to be considered [23].
An important attribute of modern EIA screening assays is to
provide clear discrimination between reactive and non-reactive
results, i.e., less clustering of results near the cutoff. Ideally, a test
should have almost no overlap at the cutoff for conﬁrmed positive
vs. negative individuals. While all three EIAs demonstrated good
discrimination of reactive vs. non-reactive signals, the Abbott 4th
gen EIA non-reactive s/c values clustered further from the cutoff
than the Siemens 4th gen EIA, whereas reactive signals clustered at
approximately the same distance. If signiﬁcant numbers of non-
reactive results for a given assay cluster near the cutoff, this may
lead to greater numbers of specimens requiring repeat screening
and supplemental testing.
The incremental cost of incorporating PNAT into the
algorithm for this high-risk population was approximately$10CAD per specimen tested (total cost $95,500). The incre-
mental PNAT cost per AHI case identiﬁed was therefore $15,917
for Siemens 3rd gen non-reactive, $23,875 for Abbott 4th gen
non-reactive, and $47,750 for Siemens 4th gen non-reactive
specimens. While PNAT after non-reactive 3rd gen screening has
been shown to be cost effective for high-risk populations [14],
the cost-effectiveness of PNAT after 4th gen screening to our
knowledge has not been studied to date [24]. For our study
population, PNAT after 4th gen screening would likely be cost-
effective given that timely diagnosis, notiﬁcation and engage-
ment into care of individuals with AHI has been shown to
reduce secondary HIV transmission [21,25,26] and the associat-
ed high lifetime medical costs [27].
In summary, we demonstrated that both PNAT and 4th gen HIV
EIAs provide an increased AHI diagnostic yield compared to 3rd
gen screening, with PNAT showing the highest incremental yield.
Based on our data and the published literature, 4th gen EIA should
become the HIV screening standard. Further studies with larger
numbers of AHI cases will be required to accurately assess the
contribution of PNAT vs. 4th gen EIAs for AHI diagnosis. While
PNAT in high incidence settings is likely to remain cost-effective, as
screening algorithms shift to 4th gen screening, the decision to
incorporate PNAT into HIV screening algorithms will need to
consider PNAT cost-effectiveness, especially when screening low-
risk populations.
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